Exelixis (NASDAQ: EXEL) STOCK RECOMMENDATION
Idea | BUY |
Buy Range | 25.75 – 26.25 |
Target | 27.75 – 28 |
StopLoss* | below 25 |
Duration | 12-14 Trading Days |
Potential Returns | 6% – 7% |
Idea | Buy Range | Target | StopLoss* | Duration | Potential Returns |
BUY | 25.75 – 26.25 | 27.75 – 28 | below 25 | 12-14 Trading Days | 6% – 7% |
* Once the first target hit, reset the StopLoss at your buying price.
Our recommendations are authentic and transparent. Find this recommendation posted in Tradingview. Be assured such records are permanent and irreversible.
Exelixis (NASDAQ: EXEL) STOCK OVERVIEW
Exelixis, Inc. is an oncology company focused on finding and marketing new treatments for difficult cancers in the U.S. It offers CABOMETYX tablets for advanced renal cell carcinoma patients who have had prior anti-angiogenic therapy, and COMETRIQ capsules for progressive metastatic medullary thyroid cancer. Both drugs are based on cabozantinib, which blocks various tyrosine kinases like MET, AXL, RET, and VEGF receptors. The company also provides COTELLIC, a MEK inhibitor for some advanced melanoma cases, and MINNEBRO, an oral hypertension blocker in Japan. Exelixis is working on zanzalintinib, a next-gen oral tyrosine kinase inhibitor targeting VEGF and MET, as well as XB002, an ADC targeting tissue factor. It has partnerships with several pharmaceutical firms and a clinical agreement with Sairopa B.V. for ADU-1805. Founded in 1994 and originally named Exelixis Pharmaceuticals, Inc., it rebranded to Exelixis, Inc. in February 2000 and is based in Alameda, California.
Stock Data | |
NASDAQ Symbol | EXEL |
Sectoral Index | Health Care |
52 Weeks High | 27.53 |
52 Weeks Low | 18.64 |
Exelixis (NASDAQ: EXEL) - RELATIVE STRENGTH

Relative Performance - Last 1 Year
Exelixis — NASDAQ —
Exelixis (NASDAQ: EXEL) - DAILY TECHNICAL ANALYSIS

- Following the breakdown of the Rising Wedge pattern, the price entered an extended consolidation phase.
- During this time, a Rounding Bottom pattern emerged on the chart.
- Once the price broke above the neckline of the Rounding Bottom, it experienced a upward movement but faced resistance near the 27.5 level.
- After a short pullback, the stock price is currently on an upward trend, with expectations that it may exceed the immediate resistance and sustain its position above that level.
Exelixis (NASDAQ: EXEL) - RSI

- Current RSI of this stock is 61.60, which indicates the strength of buyers.
Exelixis (NASDAQ: EXEL) - EMA CROSS

- The short length exponential moving average (10 EMA) has crossed the long length exponential moving average (20 EMA) from the below, generates bullish signal. Last dayโs candle has closed above all these moving averages. This suggests buyers are taking interest in this stock.
Exelixis (NASDAQ: EXEL) - ADX & DI

- Increasing ADX value above 20, indicated the strength of the trend, thereby uptrending ADX confirms the bullish or bearish supportive decisions. Along with the rising ADX, and the +DI is above (or crossing) -DI, indicates the long trades should be favoured.
CONCLUSION - Exelixis (NASDAQ: EXEL) STOCK PRICE FORECAST
Based on our stock trading advice in USA, Exelixis stock price target will be USD 27.75 – USD 28 in the next 12-14 trading sessions.